Evidence map›Paper›PMID 34639344›Full record

ArticleInternational journal of environmental research and public health2021

ABO Blood Groups and the Incidence of Complications in COVID-19 Patients: A Population-Based Prospective Cohort Study.

Salvador Domènech-Montoliu, Joan Puig-Barberà, Maria Rosario Pac-Sa, Paula Vidal-Utrillas, Marta Latorre-Poveda, Alba Del Rio-González, Sara Ferrando-Rubert, Gema Ferrer-Abad, Manuel Sánchez-Urbano, Laura Aparisi-Esteve and 14 more

Abstract read
In one paragraph

Article in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Advance in the mechanism and clinical research of myalgia in long COVID.American journal of clinical and experimental immunology · 2024
    Review
  7. Article
  8. Article
  9. Systematic Review of the Prevalence of Long COVID.Open forum infectious diseases · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Salvador Domènech-MontoliuEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Joan Puig-BarberàVaccines Research Area FISABIO, 46020 Valencia, Spain.ORCID 0000-0001-5783-0409
Maria Rosario Pac-SaPublic Health Center, Health Department 2, 12003 Castello de la Plana, Spain.
Paula Vidal-UtrillasHealth Centers I and II, Health Department 2, 12530 Borriana, Spain.
Marta Latorre-PovedaEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Alba Del Rio-GonzálezHealth Centers I and II, Health Department 2, 12530 Borriana, Spain.
Sara Ferrando-RubertHealth Centers I and II, Health Department 2, 12530 Borriana, Spain.
Gema Ferrer-AbadHealth Centers I and II, Health Department 2, 12530 Borriana, Spain.
Manuel Sánchez-UrbanoEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Laura Aparisi-EsteveCarinyena Health Center, 12540 Vila-Real, Spain.ORCID 0000-0003-4523-652X
Gema Badenes-MarquesEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Belén Cervera-FerrerEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Ursula Clerig-ArnauEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Claudia Dols-BernadHealth Center, Health Department 3, 12200 Onda, Spain.
Maria Fontal-CarcelHealth Center, Health Department 3, 12600 La Vall d'Uixó, Spain.
Lorna Gomez-LanasEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
David Jovani-SalesEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.ORCID 0000-0002-2378-3445
Maria Carmen León-DomingoVilla Fátima School, Health Department 3, 12530 Borriana, Spain.
Maria Dolores Llopico-VilanovaEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Mercedes Moros-BlascoCarinyena Health Center, 12540 Vila-Real, Spain.
Cristina Notari-RodríguezHealth Center, Health Department 3, 12200 Onda, Spain.
Raquel Ruíz-PuigEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Sonia Valls-LópezEmergency Service Hospital de la Plana, Health Department 3, 12540 Vila-Real, Spain.
Alberto Arnedo-PenaPublic Health Center, Health Department 2, 12003 Castello de la Plana, Spain.ORCID 0000-0002-1071-0984

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After a COVID-19 outbreak in the Falles festival of Borriana (Spain) during March 2020, a cohort of patients were followed until October 2020 to estimate complications post-COVID-19, considering ABO blood groups (ABO). From 536 laboratory-confirmed cases, 483 completed the study (90.1%) carried by the Public Health Center of Castelló and the Emergency and Microbiology and Clinical Analysis of Hospital de la Plana Vila-real. The study included ABO determination and telephone interviews of patients. The participants had a mean age of 37.2 ± 17.1 years, 300 females (62.1%). ABO were O (41.4%), A (45.5%), B (9.1%), and AB (3.9%). We found no difference in the incidence of COVID-19 infections. A total of 159 (32.9%) patients reported one or more post-COVID-19 complications with divergent incidences after adjustment: O (32.3%), A (32.6%), B (54.1%), and AB (27.6%); B groups had more complications post-COVID-19 when compared with O group (adjusted relative risk [aRR] 95% confidence interval [CI] 1.68, 95% CI 1.24-2.27), and symptoms of fatigue (1.79, 95% CI 1.08-2.95), myalgia (2.06, 95% CI 1.10-3.84), headache (2.61, 95% CI 1.58-4.31), and disorder of vision (4.26 95% CI 1.33-13.60). In conclusion, we observed significant differences in post-COVID-19 complications by ABO, with a higher incidence in B group. Additional research is justified to confirm our results.

Indexed as

ABO Blood-Group SystemCOVID-19AdultCohort StudiesFemaleHumansIncidenceMiddle AgedProspective StudiesSARS-CoV-2Young AdultABO Blood-Group SystemABO blood groupscohortcomplicationsCOVID-19incidencepopulation basedpost-COVID-19symptoms

Identifiers

PMID34639344
PMCPMC8507737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.